Related Experiment Video
Updated: Jul 18, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Adalimumab therapy for recalcitrant pyoderma gangrenosum
Margaret A Fonder1, Deborah L Cummins, Benjamin D Ehst
1Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Objective:
To describe a patient with treatment-refractory pyoderma gangrenosum and the outcome of a novel therapeutic approach.
Methods:
Case report and review of the literature.
Results:
A patient with inflammatory bowel disease developed severe pyoderma gangrenosum while receiving treatment with the chimeric anti-TNF-alpha antibody infliximab. Despite subsequent trials of numerous immunosuppressive and immunomodulatory medications, the dermatologic disease progressed. The patient's ulcers finally resolved when treatment with adalimumab, a fully humanized monoclonal antibody specific for TNF-alpha, was initiated.
Conclusions:
We report a novel application of the TNF-alpha inhibitor, adalimumab, in the treatment of pyoderma gangrenosum.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Acute Pyelonephritis II: Diagnostic Studies and Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Peripheral Artery Disease III: Interprofessional Care